Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Bristol Myers Squibb (BMS) witnessed the largest growth in market capitalisation of 24.6% to $105bn in Q3 2024, fuelled by ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of ...

The biotech company is developing a drug that targets two different cancer vulnerabilities, including a protein hit by Merck & Co.’s blockbuster Keytruda. Ottimo’s double-barreled approach is similar ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The board of Olympus has told Stefan Kaufmann – its President and CEO – to walk the plank following allegations Kaufmann purchased “illegal drugs”. In a statement to the Tokyo Stock ...